Use of peptide-based vaccines as therapeutics aims to elicit immune responses through antigenic epitopes derived from tumor antigens. Peptide-based vaccines are easily synthesized and lack significant side-effects when given in vivo. Peptidebased vaccine therapy against several cancers including urological cancers has made progress for several decades, but there is no worldwide approved peptide vaccine. Peptide-based vaccines might prolong overall survival rate and spare normal tissue because of its low toxic effect. Table 1 
Peptide-based vaccines might prolong overall survival rate and spare normal tissue because of its low toxic effect. Table 1 14 In this review, we introduce the mechanism of peptide-based vaccine therapy, recent clinical trials for urological cancers using peptide vaccines, and perspectives of peptide-based vaccine therapy.
| MECHANISM OF ANTITUMOR EFFECT BY PEPTIDE-BASED VACCINES
Tumor-associated antigens are expressed in tumor cells and can be recognized by T lymphocytes, resulting in activation of the immune system. 15 A TAA peptide vaccine, when injected into cancer patients, binds with the restricted MHC molecule expressed in APC. 16 The peptide/MHC complex is then transported to the cell surface after intracellular processing and is recognized by the TCR on the surface of T cells, leading to activation of T lymphocytes. 17 Therefore, a peptide cancer vaccine may elicit a specific immune response against tumors.
Because CTL have the ability to recognize TAA-derived CTL epi- [29] [30] [31] We have also tested these peptides in clinical investigations against several urological cancers. Recently, a subsequent analysis suggested that patients in the placebo group who were later given cryopreserved immune cells as part of a planned crossover may have performed better clinically than would have been expected. 33 Therefore, the results of the phase III study may have underestimated the actual therapeutic benefit. There has been remarkable progress in cancer immunotherapy using anti-CTLA4 antibody for prostate cancer. However, a phase III trial using anti-CTLA4 antibody (ipilimumab) for CRPC patients showed no significant difference between the ipilimumab group and the placebo group in terms of overall survival. 34 Fenoglio et al 35 confirmed the safety and immunological response against prostate cancers by using a multipeptide, dual-adjuvant telomerase vaccine called GX301, which is composed of four telomerase peptides (peptide 540-548, peptide 611-626, peptide 672-686, and peptide 766-780) and two adjuvants, MontanideISA-51 and Imiquimod. Another approach is a PPV, which uses multiple tumor-associated antigens based on the pre-existing host immunity.
| PROSTATE CANCER
Two phase II studies have been reported in patients post-docetaxel, 6 with one showing a longer OS time. 5 Recently, another phase II study showed a delay in PFS of PSA in patients with chemotherapy na€ ıve CRPC. 7 Thirty-seven patients received peptide vaccinations and 35 received dexamethasone alone. PSA PFS was significantly longer in the vaccination group than in the dexamethasone group (22.0 vs 7.0 months; P = .0076). Median OS was also significantly longer in the vaccination group (73.9 vs 34.9 months; P = .00084).
F I G U R E 1 Overview of developed peptide vaccine treatment by our strategy. We constructed a genome-wide expression profile of bladder cancer using cDNA microarray, and identified several oncoantigens. We subsequently detected that stimulation using human leukocyte antigen (HLA)-A-restricted oncoantigen-derived epitope peptides induces specific CTL. We conducted a clinical study using these novel peptide vaccines for patients with urological cancer. CDCA1, cell division associated 1; DEPDC1, DEP domaincontaining 1; HIG2, hypoxia-inducible protein 2; MPHOSPH1, M-phase phosphoprotein 1
The researchers suggested that early-stage CRPC with PS of 0 or 1 and PSA <10 ng/mL may receive preferable clinical benefits from peptide vaccine treatment. A randomized phase III study is now progressing for patients with early-stage CRPC.
We previously identified CDCA1, which was also overexpressed in various cancers including prostate cancer. 25 We screened and identified an HLA-A*2402-restricted epitope peptide, CDCA1-A24-56-64, that has a high antigenic activity to induce CTL. 29 Recently,
we reported a phase I clinical trial for patients with CRPC using a CDCA1 peptide vaccination. 4 Twelve patients having HLA-A*2402
with CRPC after failure of docetaxel chemotherapy were enrolled. Peptide-specific CTL responses using ELISPOT assay and dextramer assay were observed in three patients receiving the 1.0 mg dose and could have a high antigenic activity to induce CTL. 30 Recently, we reported a phase I clinical trial using the HIG2-9-4 peptide for patients with advanced RCC. 8 HIG2-9-4 peptide vaccine treatment was tolerable and effectively induced peptide-specific CTL in RCC patients. This novel peptide vaccine therapy for RCC seems to be promising.
| UROTHELIAL CANCER
Intravesical BCG therapy against bladder cancer, which has been used for a long time, is a non-specific immunotherapy and is known We have previously reported two novel oncoantigens, DEP domain-containing 1 (DEPDC1) and M-phase phosphoprotein 1 (MPHOSPH1), through expression profile analysis of bladder cancers. 27, 28 HLA-A*24:02-restricted epitope peptides from these antigens have been shown to induce strong CTL, which were able to kill tumor cells expressing these antigens in a HLA-restricted way. 31 More recently, we reported a phase I/II study using these peptide vaccines in advanced UC patients who were resistant to cisplatinbased chemotherapy, as a sponsored initiated clinical trial (Figure 4) . | 555
In the phase II part, 32 patients were randomized to receive either 1 mg or 2 mg to evaluate the difference in CTL induction and safety. S-288310 was safe and well tolerated. There was no difference in CTL induction rate between the 1-mg (100%) and the 2-mg (80.0%) groups. Of the 32 patients receiving S-288310 in the phase II part, the most frequent drug-related AE was an injection site reaction that was observed in 29 patients (90.6%), but none of the patients discontinued treatment as a result of these reactions and no dose relationship in the frequency and severity was observed.
Objective response rate of the 32 patients was 6.3% and disease control rate was 56.3%. Median OS rates for patients vaccinated with S-288310 after one regimen of chemotherapy, two regimens, or three or more were 14.4, 9.1 and 3.7 months, respectively, and 32.2% of patients post first-line treatment were alive at 2 years. OS of patients who showed CTL induction to both peptides was longer than that of those with CTL induction to no or one peptide. We concluded that S-288310 was well tolerated and effectively induced peptide-specific CTL, which were correlated with longer survival for patients with UC of the bladder. Our findings support the concept of cancer peptide vaccine to prime antitumor responses and warrant further clinical trials.
| COMBINATION THE RAPY USING PE PTIDE-BASED VACCINE
The best combination appears to be that involving immunomodulatory agents 47 which can amplify T-cell expansion over time and increase the duration of the effect of vaccination. 48 In fact, the only peptide-based successful phase III trial included a combination of the gp100 peptide and a high dose of IL-2 in metastatic melanoma peutics. This situation is now even more promising than before and we predict that such new peptide-based trials will provide other clinical successes in urological cancers.
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